Author Archives: admin


Stem Cell Clinic > Articles by: admin

New protocol could signal shift in bone regenerative medicine – Yahoo Finance

By Adult Stem Cells

A new, safe and efficient way to coax stem cells into bone cells is reported in a recently published article from STEM CELLS Translational Medicine (SCTM).

DURHAM, N.C., Jan. 6, 2020 /PRNewswire-PRWeb/ -- A new, safe and efficient way to coax stem cells into bone cells is reported in a recently published article from STEM CELLS Translational Medicine (SCTM). The protocol, developed by researchers at the University of Sydney, Australian Research Centre (ARC) for Innovative BioEngineering, could lead to a shift in the treatment of bone regenerative medicine.

Large bone defects and loss due to cancer or trauma can result in scar tissue that impairs the bones' ability to repair and regenerate. The current gold standard therapy, autografting, has inherent drawbacks, including limited availability and donor site morbidity. This leaves researchers seeking an alternative source of bone cells and makes bone tissue engineering a growing field with considerable translational potential.

"The success of induced pluripotent stem cell (iPSC) technology to reprogram fibroblasts into progenitor cells of various lineages offers an exciting route for tissue repair and regeneration," said Zufu Lu, Ph.D., a member of the University of Sydney's Biomaterials and Tissue Engineering Research Unit and a research associate at the ARC for Innovative BioEngineering. He is a co-lead investigator of the SCTM study, along with Professor Hala Zreiqat, Ph.D., head of the research unit and director of the ARC Training Centre for Innovative BioEngineering.

"However, while iPSC technology represents a potentially unlimited source of progenitor cells and allows patients to use their own cells for tissue repair and regeneration thus posing little or no risk of immune rejection the technology has several constraints. Among them are the requirement for complex reprogramming using the Yamanaka factors (Oct3/4, Sox2, Klf4, c-Myc). To add to the complexity, specific stimuli are required to direct iPSCs to re-differentiate to progenitor cells of the lineage of interest.

"In addition," Dr. Lu said, "any remaining iPSCs pose the risk of tumors following implantation."

One potential way around this, as demonstrated by recent studies, is through the direct reprogramming of fibroblasts into bone cells. "Fibroblasts are morphologically similar to osteoblasts. Their similar transcriptomic profiles led us to hypothesize that distinct factors produced by osteoblasts may be capable of coaxing fibroblasts to become osteoblast-like cells," Prof. Zreiqat said.

Previous studies aimed at using fibroblasts to produce various cell types relied on the genetic manipulation of one or more transcription regulators. But just as with iPSCs, reprogramming fibroblasts in this manner has its own inherent technical and safety issues. The Lu-Zreiqat team, however, surmised that an approach employing natural factors might just allow better control over reprogramming and improve the safety.

"Unlike genetic reprogramming, chemical induction of cell reprogramming is generally rapid and reversible, and is also more amenable to control through factor dosage and/or combinations with other molecules," Dr. Lu explained.

The team initially determined that media conditioned by human osteoblasts can induce reprogramming of human fibroblasts to functional osteoblasts. "Next," said Prof. Zreiqat, "our proteomic analysis identified a single naturally bioactive protein, insulin growth factor binding protein-7 (IGFBP7), as being significantly elevated in media conditioned with osteoblasts, compared to those with fibroblasts."

This led them to test IGFBP7's ability as a transcription factor. They found it, indeed, successfully induced a switch from fibroblasts to osteoblasts in vitro. They next tested it in a mouse model and once again experienced success when the fibroblasts produced mineralized tissue. The switch was associated with senescence and dependent on autocrine IL-6 signaling.

"The approach we describe in our study has significant advantages over other commonly used cell sources including iPSCs and adult mesenchymal stem cells," Dr. Lu and Prof Zreiqat concluded.

"Bone tissue engineering is a growing field where cell therapies have considerable translational potential, but current cell-based approaches face limitations," said Anthony Atala, M.D., Editor-in-Chief of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine. "The novel observation described in this study could potentially lead to a shift in the current paradigm of bone regenerative medicine."

Story continues

This study was conducted in collaboration with the Charles Perkins Centre and the Children's Hospital at Westmead, University of Sydney.

The full article, "Reprogramming of human fibroblasts into osteoblasts by insulin-like growth factor binding protein 7," can be accessed at https://stemcellsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/sctm.19-0281.

About STEM CELLS Translational Medicine: STEM CELLS Translational Medicine (SCTM), co-published by AlphaMed Press and Wiley, is a monthly peer-reviewed publication dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices. SCTM is the official journal partner of Regenerative Medicine Foundation.

About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes two other internationally renowned peer-reviewed journals: STEM CELLS (http://www.StemCells.com), celebrating its 38th year, is the world's first journal devoted to this fast paced field of research. The Oncologist (http://www.TheOncologist.com), also a monthly peer-reviewed publication, entering its 25th year, is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. All three journals are premier periodicals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines.

About Wiley: Wiley, a global company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical and scholarly journals, combined with our digital learning, assessment and certification solutions, help universities, learned societies, businesses, governments and individuals increase the academic and professional impact of their work. For more than 200 years, we have delivered consistent performance to our stakeholders. The company's website can be accessed at http://www.wiley.com.

About Regenerative Medicine Foundation (RMF): The non-profit Regenerative Medicine Foundation fosters strategic collaborations to accelerate the development of regenerative medicine to improve health and deliver cures. RMF pursues its mission by producing its flagship World Stem Cell Summit, honouring leaders through the Stem Cell and Regenerative Medicine Action Awards, and promoting educational initiatives.

SOURCE STEM CELLS Translational Medicine

Read the original here:
New protocol could signal shift in bone regenerative medicine - Yahoo Finance

Researchers at Baylor College of Medicine Discover How to Improve Bone Repair – Gilmore Health News

By Adult Stem Cells

Researchers at Baylor College of Medicine have discovered a new mechanism that helps maintain and repair bones in adults. Ultimately, this could help develop new therapeutic strategies to improve bone healing.

Knee Bones

Osteoporosis is a skeletal disease characterized by reduced bone density and changes in the microarchitecture of bones. These changes weaken the bone and increase the risk of fractures.

Osteoporosis develops particularly in older people. Today, a new study could eventually lead to the development of therapeutic strategies to improve bone regeneration in these patients. Results published in the journal Cell Stem Cell on the 5th December 2019 have laid out a new mechanism that contributes to the maintenance and repair of bones in adults.

Adult bone repair relies on the activation of bone stem cells, which still remain poorly characterized. Bone stem cells have been found both in the bone marrow inside the bone and also in the periosteum: the outer layer of tissue that envelopes bone. Previous studies have shown that these two populations of stem cells share many characteristics; however, they also have unique functions and specific regulatory mechanisms, said Dr. Dongsu Park, assistant professor of molecular and human genetics, pathology and immunology at Baylor College of Medicine.

Of these two populations, periosteal stem cells are the least known. Although scientists know that this is a heterogeneous population of cells that can contribute to the thickness, formation, and repair of bone fractures, no one has yet been able to distinguish between the different subtypes of bone stem cells in order to study the regulation of their different functions.

Read Also:HGH Is Now A Solid Treatment For Osteoporosis According To Studies

Here, however, Dr. Dongsu Park and colleagues were able to develop a technique in mice to identify different subpopulations of periosteal stem cells, define their contribution to the repair of bone fractures and identify the specific factors that regulate their migration and proliferation under physiological conditions.

The researchers identified a specific subset of stem cells that contribute to lifelong bone regeneration in adults. They also observed that periosteal stem cells react to inflammatory molecules, chemokines, which are normally produced in bone injuries.

In detail, periosteal stem cells have receptors that bind to the CCL5 chemokine. The CCL5 chemokine sends a signal to the cells to migrate to the injured bone and repair it. By suppressing the CCL5 gene in rats, the researchers found defects in bone repair that delayed healing. However, when they gave CCL5 to rats that had lost CCL5, the bones recovered faster.

Read Also:The Exciting Future of Joint and Cartilage Repair

Our findings contribute to a better understanding of the healing of adult bones. We believe this is one of the first studies to show that bone stem cells are heterogeneous and that different subtypes have unique properties that are regulated by specific mechanisms, said Dr. Dongsu Park.

In conclusion, this study has allowed for the identification of different stem cell subtypes and their distinguishing markers and their roles in bone repair. This discovery gives insight into new therapeutic strategies for the treatment of bone damage in adults, particularly in the setting of osteoporosis or diabetes. Indeed, people with diabetes may be prone to falls and fractures due to neurological, visual or renal complications. In addition, bone fragility in diabetics is likely to be due to changes in bone remodeling and, in particular, an increase in bone resorption.

Read Also:Implants from Own Stem Cells May Offer Solution to Back Pain, Researchers Say

https://www.cell.com/cell-stem-cell/fulltext/S1934-5909(19)30458-8?

Mitochondrial Damage Can Cause Osteoporosis According to Study

Man Destroys Kidneys With Too Much Vitamin D

Could Stem Cell Injections Get Rid of Low Back Pain Completely?

Natural Remedies You May Want to Try For Arthritis

To Grow Taller With Limb Lengthening Surgery Is Not For The Fainthearted

HGH Deficiency in Children: The Latest Facts

Hormones Replacement Therapy for Graceful Aging A Major Trend

Go here to see the original:
Researchers at Baylor College of Medicine Discover How to Improve Bone Repair - Gilmore Health News

Gene editing breakthroughs that cured genetic diseases in 2019 – The Star Online

By Stem Cell Medicine

IN the summer of 2019, a mother in Nashville, Tennessee in the United States, with a seemingly incurable genetic disorder finally found an end to her suffering by editing her genome.

Victoria Grays recovery from sickle cell disease, which had caused her painful seizures, came in a year of breakthroughs in one of the hottest areas of medical research gene therapy.

I have hoped for a cure since I was about 11, the 34-year-old said.

Since I received the new cells, I have been able to enjoy more time with my family without worrying about pain or an out-of-the-blue emergency.

Over several weeks, Grays blood was drawn so that doctors could get to the cause of her illness stem cells from her bone marrow that were making deformed red blood cells.

The stem cells were sent to a Scottish laboratory, where their DNA was modified using Crispr/Cas9 pronounced Crisper a new tool informally known as a molecular scissors.

The genetically-edited cells were transfused back into Grays veins and bone marrow. A month later, she was producing normal blood cells.

Medics warn that caution is necessary, but theoretically, she has been cured.

This is one patient. This is early results. We need to see how it works out in other patients, said her doctor, Haydar Frangoul, at the Sarah Cannon Research Institute in Nashville.

But these results are really exciting.

In Germany, a 19-year-old woman was treated with a similar method for a different blood disease beta thalassemia.

She had previously needed 16 blood transfusions per year. Nine months later, she is completely free of that burden.

For decades, the DNA of living organisms such as corn and salmon has been modified. But Crispr, invented in 2012, made gene editing more widely accessible.

It is much simpler than preceding technology, cheaper and easy to use in small labs.

The technique has given new impetus to the perennial debate over the wisdom of humanity manipulating life itself.

Its all developing very quickly, said French geneticist Emmanuelle Charpentier, one of Crisprs inventors and the co-founder of Crispr Therapeutics, the biotech company conducting the clinical trials involving Gray and the German patient.

Gene cures

Crispr was the latest breakthrough in a year of great strides in gene therapy, a medical adventure that started three decades ago, when the first TV telethons were raising money for children with muscular dystrophy.

Scientists practising the technique insert a normal gene into cells containing a defective gene.

It does the work the original could not, such as making normal red blood cells in Grays case or making tumour-killing super white blood cells for a cancer patient.

Crispr goes even further: instead of adding a gene, the tool edits the genome itself.

After decades of research and clinical trials on a genetic fix to genetic disorders, 2019 saw a historic milestone: approval to bring to market the first gene therapies for a neuromuscular disease in the US and a blood disease in the European Union.

They join several other gene therapies bringing the total to eight approved in recent years to treat certain cancers and an inherited blindness.

Serge Braun, the scientific director of the French Muscular Dystrophy Association, sees 2019 as a turning point that will lead to a medical revolution.

Twenty-five, 30 years, thats the time it had to take, he said. It took a generation for gene therapy to become a reality. Now, its only going to go faster.

Just outside Washington, at the US National Institutes of Health (NIH), researchers are also celebrating a breakthrough period.

We have hit an inflection point, said US NIHs associate director for science policy Carrie Wolinetz.

These therapies are exorbitantly expensive, however, costing up to US$2 million (RM8.18 million) meaning patients face grueling negotiations with their insurance companies.

They also involve a complex regimen of procedures that are only available in wealthy countries.

Gray spent months in hospital getting blood drawn, undergoing chemotherapy, having edited stem cells reintroduced via transfusion and fighting a general infection.

You cannot do this in a community hospital close to home, said her doctor.

However, the number of approved gene therapies will increase to about 40 by 2022, according to Massachusetts Institute of Technology (MIT) researchers.

They will mostly target cancers and diseases that affect muscles, the eyes and the nervous system.

In this Oct 10, 2018, photo, He speaks during an interview at his laboratory in Shenzhen, China. The scientist was recently sentenced to three years in prison for practicing medicine illegally and fined 3 million yuan (RM1.76 million). AP

Bioterrorism potential

Another problem with Crispr is that its relative simplicity has triggered the imaginations of rogue practitioners who dont necessarily share the medical ethics of Western medicine.

In 2018 in China, scientist He Jiankui triggered an international scandal and his excommunication from the scientific community when he used Crispr to create what he called the first gene-edited humans.

The biophysicist said he had altered the DNA (deoxyribonucleic acid) of human embryos that became twin girls Lulu and Nana.

His goal was to create a mutation that would prevent the girls from contracting HIV (human immunodeficiency virus), even though there was no specific reason to put them through the process.

That technology is not safe, said Kiran Musunuru, a genetics professor at the University of Pennsylvania, explaining that the Crispr scissors often cut next to the targeted gene, causing unexpected mutations.

Its very easy to do if you dont care about the consequences, he added.

Despite the ethical pitfalls, restraint seems mainly to have prevailed so far.

The community is keeping a close eye on Russia, where biologist Denis Rebrikov has said he wants to use Crispr to help deaf parents have children without the disability.

There is also the temptation to genetically edit entire animal species, e.g. malaria-causing mosquitoes in Burkina Faso or mice hosting ticks that carry Lyme disease in the US.

The researchers in charge of those projects are advancing carefully however, fully aware of the unpredictability of chain reactions on the ecosystem.

Charpentier doesnt believe in the more dystopian scenarios predicted for gene therapy, including American biohackers injecting themselves with Crispr technology bought online.

Not everyone is a biologist or scientist, she said.

And the possibility of military hijacking to create soldier-killing viruses or bacteria that would ravage enemies crops?

Charpentier thinks that technology generally tends to be used for the better.

Im a bacteriologist -- weve been talking about bioterrorism for years, she said. Nothing has ever happened. AFP Relaxnews

More:
Gene editing breakthroughs that cured genetic diseases in 2019 - The Star Online

Radical treatment of oral infection is not necessary before stem cell transplantation, says study – ANI News

By Stem Cell Treatment

ANI | Updated: Jan 05, 2020 19:56 IST

Washington D.C. [USA], Jan 5 (ANI): A recent scientific study suggests that contrary to the conventional belief, oral infection has no association with the risk of patients that people developing serious infectious diseases within six months of undergoing stem cell transplantation.The study was conducted by the researchers of the University of Helsinki and was published in the journal - PLOS ONE.During the study, researchers investigated to find out if oral infections are associated with infectious complications as well as mortality rate after stem cell transplantation."Contrary to our assumptions, untreated oral infections had no connection with post-stem cell transplantation survival during the six-month follow-up period. Another surprise was that they had no link with any serious infectious complications occurring during the follow-up period," said lead researcher Tuomas Waltimo.The process of hematopoietic stem cell transplantation is used for treating cancers and other severe blood and autoimmune diseases.Owing to long durations required for recovery of the human immune system following stem cell transplantation procedure, patients generally have a heightened risk of infections. (ANI)

Continue reading here:
Radical treatment of oral infection is not necessary before stem cell transplantation, says study - ANI News

The 2020s: An NJIT researcher gives us a glimpse at the future of technology – NJ.com

By Stem Cell Treatment

By Atam Dhawan

As our civilization evolves, so do our expectations of technology. Together, they demonstrate how dramatic advances in robots, nanotechnology-enabled sensors and high-powered computing will continue to change and evolve our society. Importantly, many of these technologies, including smart robots, point-of-care devices and machine intelligence, will empower individuals to enjoy their lives more purposefully.

Here is my list of new goalposts for the next decade in three spheres: health care, environmental sustainability and technology-assisted living.

Healthcare:

Sustainable Environment:

Technology-Assisted Living:

Atam Dhawan is the senior vice provost for research at NJIT, a distinguished professor of electrical and computer engineering and an inventor. With several issued patents, some commercialized, Dhawan was inducted into the National Academy of Inventors in 2015 for his work on point-of-care technologies in health care. He serves as the chair of the National Institutes of Healths point-of-care research network.

The Star-Ledger/NJ.com encourages submissions of opinion. Bookmark NJ.com/Opinion. Follow us on Twitter @NJ_Opinion and on Facebook at NJ.com Opinion. Get the latest news updates right in your inbox. Subscribe to NJ.coms newsletters.

More here:
The 2020s: An NJIT researcher gives us a glimpse at the future of technology - NJ.com

Top 10 ALS Stories of 2019 – ALS News Today

By Stem Cell Treatment

Throughout 2019, ALS News Today brought you daily coverage of key findings, treatment developments, clinical trials, and other events related to amyotrophic lateral sclerosis (ALS).

As a reminder of what mattered most to you in 2019, here are the top 10 most-read articles of last year with a brief description of what made them interesting and relevant to the ALS community.

We look forward to reporting more news to patients, family members, and caregivers dealing with ALS during 2020.

No. 10 Experimental Gene Therapy Successfully Silences Key ALS Gene C9orf72, Preclinical Studies Show

A tale of two preclinical studies showed that a gene therapy candidate targeting a key ALS mutation in the C9orf72 gene was able to lessen the buildup of toxic RNA clumps and reduce the activity of the mutated gene in cells collected from a patient with frontotemporal dementia (FTD) and a mouse model of ALS.

Developed by uniQure,the therapy is designed to silence thedisease-causing gene. It works by delivering microRNAs (miRNAs) RNA molecules that regulate gene expression that target the mutated C9orf72s RNA for degradation. The results supported the continuation of uniQures gene therapy program in ALS and FTD, the company said.

No. 9 Altered Gut Microbiota in ALS Patients Could Drive Digestive Problems, Study Suggests

In the summer, a small study discovered an altered composition of gut microbes in people with ALS, which could drive digestive problems in those with the disease.

Using genetics, a research team in China found that fecal samples of people with ALS have an increase in harmful microbes of the phylum Firmicutes and a decrease in beneficial microorganisms called Bacteroidetes. The resulting poor gastrointestinal health may lead to a decline in the guts digestion and metabolism functions.

No. 8 Ibudilast-Rilutek Therapy Combo Closer to U.S. Patent for ALS and Other Neurodegenerative Diseases

At the beginning of the year, U.S. biopharmaceutical MediciNova received a notice of allowance stating that its request for a patent covering a combination of its investigational therapy ibudilast (MN-166) plus Rilutek (riluzole) was being consideredby the U.S. Patent and Trademark Office.

Ibudilast is a small molecule that reduces the activity of immune cells in the brain while supporting the growth of motor neurons, those lost in people with ALS. In a Phase 2 trial (NCT02238626), the treatment was found to work well in combination with Sanofis approved therapy Rilutek, improving patients functional activity, quality of life, and muscle strength.

The notice of allowance was the final step toward patent registration. Such registration will provide patent protection until November 2035 to the combination, for use in treating ALS and other neurodegenerative diseases.

No. 7 MediciNova Launches Phase 2b/3 Trial of Ibudilast for ALS

In June, MediciNova launched a Phase 2b/3 clinical trial to continue studying ibudilast as an add-on therapy to Rilutek. The multicenter, double-blind study (NCT04057898) will recruit approximately 230 participants, who will be randomly selected to receive either ibudilast plus Rilutek or a placebo plus Rilutek for 12 months.

The trials main goal is to study ibudilasts impact on ALS progression and functional disability by determining changes in the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) score between the beginning and end of the treatment period. Secondary objectives include changes in patients muscle strength, quality of life, and respiratory function. The study also will evaluate the safety and tolerability profile of ibudilast.

No. 6 FDA Approves Pivotal Phase 2b/3 Trial for Ibudilast in ALS Patients

Just a few months earlier, MediciNova had received approval from the U.S. Food and Drug Administration (FDA) to initiate this trial. Eligible patients must have had the disease for no more than 18 months and present just mild disability.

During the trial, patients will receive Rilutekfor at least 30 days before starting a regimen of either 100 mg per day of ibudilast or a placebo for a period of 12 months. Participants may then enter an extension phase in which they will be offered the ibudilast combination for an additional six months. Top-line data is expected by December 2021.

No. 5 Phase 3 Trial of NurOwn Cell Therapy Fully Enrolls 200 Patients, BrainStorm Announces

The Phase 3 trial evaluatingBrainStorm Cell Therapeuticss cell therapy candidateNurOwn completed patient enrollment in October. The 200 participants will receive three administrations of NurOwn, or a placebo, into the spinal canal every two months. The primary goals are to demonstrate the therapys safety and its ability to slow disease progression.

A cell-based therapy, NurOwn works by removing specific stem cells from patients and converting them to cells that produce molecules that promote nerve tissue growth and survival. The modified cells are then returned to the patient to stimulate nerve tissue growth. NurOwn aims to safely improve abilities like swallowing, speech, handwriting, and walking in people with ALS.

No. 4 High-dose Vitamin B12 May Improve ALS Prognosis if Started Early, Study Suggests

A long-term Phase 2/3 study examining vitamin B12 as a treatment for ALS found that ultra-high doses of methylcobalamin, the physiologically active form of this vitamin, may extend survival and slow the decline in functional capacity, compared with a placebo.

The study included 373 patients, diagnosed fewer than three years earlier, across 51 sites in Japan. However, the benefits were only seen in patients diagnosed less than one year before taking the supplements, and only a trend was observed.

No. 3 CuATSM Therapy May Slow ALS Progression, Improving Cognition and Respiration in Patients, Phase 1 Trial Shows

Results from a Phase 1 clinical trial (NCT02870634) showed that CuATSM a small molecule able to selectively deliver copper to cells with damaged mitochondria slowed disease progression and improved the respiratory and cognitive function of people with ALS.

Damaged mitochondria are considered a hallmark of several neurodegenerative diseases, including ALS, and delivering copper is thought to restore the health of these organelles. Developer Collaborative Medicinal Development (CMD) began testing CuATSM in patients with sporadic and familial ALS in 2016.CMD is now planning to launch a randomized, placebo-controlled clinical trial for CuATSM to confirm these results.

No. 2 Bacteria and Fungi Found in Central Nervous System of ALS Patients, Study Reports

In March, a study discovered several species of bacteria and fungi living in the central nervous system (CNS) of people with ALS, suggesting that patients have coexisting bacterial and fungal infections.

The study built on prior research suggesting that ALS might be caused by a fungal infection. Researchers then examined frozen CNS tissue from 11 ALS patients to assess whether bacterial infections accompany fungal infections. Bacterial DNA was found in different regions of the CNS and the presence of bacteria was confirmed in neural tissue samples.

No. 1 Nerve Injury May Trigger Onset, Progression of ALS Symptoms, Rat Study Suggests

Our most-read article of 2019reported that small nerve damage may serve as an ALS trigger. Such damage may accelerate motor symptoms in rats carrying a mutation in the SOD1 gene,one of the 40 genes associated with ALS development in humans.

While rats without the mutation completely recovered leg function four weeks after induced damage to the sciatic nerve, located in the leg, SOD1-mutated animals were unable to fully recover. These rats also lost function in the uninjured leg, likely as a consequence of sustained immune activation and more severe neurodegeneration.

The induced nerve damage mimics head injury and trauma in human patients, which could explain the higher prevalence of the disease among war veterans and professional athletes.

***

At ALS News Today, we hope these stories and our regular reporting throughout 2020 contribute to informing and improving the lives of everyone affected by ALS.

We wish all our readers a happy 2020.

Total Posts: 6

Ins holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Cincias e Tecnologias and Instituto Gulbenkian de Cincia. Ins currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.

Excerpt from:
Top 10 ALS Stories of 2019 - ALS News Today

Stem Cell Therapy Market Size, Outlook on Key Growth Trends, Factors and Forecast to 2026 – ReportsPioneer

By Stem Cell Treatment

New Jersey, United States, The report is a brilliant presentation of critical dynamics, regional growth, competition, and other important aspects of the Stem Cell Therapy Market. The factual, unbiased, and thorough assessment of the global Stem Cell Therapy market presented in the report assures players of access to much-needed information and data to plan effective growth strategies. The report has made a brilliant attempt to provide a comprehensive research study on industry value chain, major companies, deployment models, and key opportunities, drivers, and restraints of the global Stem Cell Therapy market. It shows how the global Stem Cell Therapy market will advance or lack growth during each year of the forecast period. Readers are offered with detailed and near-accurate predictions of CAGR and market size of the global Stem Cell Therapy market and its important segments.

Global Stem Cell TherapyMarketwas valued at USD 86.62 million in 2016 and is projected to reach USD 221.03million by 2025, growing at a CAGR of 10.97% from 2017 to 2025.

Besides an exhaustive evaluation of leading trends of the global Stem Cell Therapy market, the report offers deep analysis of market development and future market changes. It includes Porters Five Forces analysis, PESTLE analysis, and qualitative as well as quantitative analysis for complete research on the global Stem Cell Therapy market. It closely focuses on technological development of the global Stem Cell Therapy market and its impact on the business of market players. With the help of the report, players will be able to become familiar with production and consumption trends of the global Stem Cell Therapy market.

Request a Sample Copy of this report @https://www.verifiedmarketresearch.com/download-sample/?rid=24113&utm_source=RPN&utm_medium=009

Top 10 Companies in the Global Stem Cell Therapy Market Research Report:

Vendor Landscape Analysis

The competitive landscape of the global Stem Cell Therapy market is extensively researched in the report. The analysts have largely concentrated on company profiling of major players and also on competitive trends. All of the companies studied in the report are profiled on the basis of production, revenue, growth rate, markets served, areas served, market share, and market growth. The report will help readers to study significant changes in market competition, the level of competition, and factors impacting future market competition. It discusses important target market strategies that leading players are expected to adopt in future. In addition, it throws light on future plans of key players.

Market Segmentation

The report offers deep insights into leading segments of the global Stem Cell Therapy market and explains key factors helping them to collect a larger share. It provides accurate growth rate and market size achieved by each segment during the forecast period. This will help players to identify lucrative segments and plan out specific strategies to gain maximum profit from them. The report also includes sales growth, revenue, and price changes observed in important segments. Most importantly, the segmental analysis equips players with useful information and data to make the best of opportunities available in different segments.

Regions Covered in the Global Stem Cell Therapy Market:

Ask for Discount @https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24113&utm_source=RPN&utm_medium=009

Table of Content

1 Introduction of Stem Cell Therapy Market

1.1 Overview of the Market 1.2 Scope of Report 1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining 3.2 Validation 3.3 Primary Interviews 3.4 List of Data Sources

4 Stem Cell Therapy Market Outlook

4.1 Overview 4.2 Market Dynamics 4.2.1 Drivers 4.2.2 Restraints 4.2.3 Opportunities 4.3 Porters Five Force Model 4.4 Value Chain Analysis

5 Stem Cell Therapy Market, By Deployment Model

5.1 Overview

6 Stem Cell Therapy Market, By Solution

6.1 Overview

7 Stem Cell Therapy Market, By Vertical

7.1 Overview

8 Stem Cell Therapy Market, By Geography

8.1 Overview 8.2 North America 8.2.1 U.S. 8.2.2 Canada 8.2.3 Mexico 8.3 Europe 8.3.1 Germany 8.3.2 U.K. 8.3.3 France 8.3.4 Rest of Europe 8.4 Asia Pacific 8.4.1 China 8.4.2 Japan 8.4.3 India 8.4.4 Rest of Asia Pacific 8.5 Rest of the World 8.5.1 Latin America 8.5.2 Middle East

9 Stem Cell Therapy Market Competitive Landscape

9.1 Overview 9.2 Company Market Ranking 9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview 10.1.2 Financial Performance 10.1.3 Product Outlook 10.1.4 Key Developments

11 Appendix

11.1 Related Research

Request Customization of Report @ https://www.verifiedmarketresearch.com/product/Stem-Cell-Therapy-Market/?utm_source=RPN&utm_medium=009

Highlights of Report

About Us:

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne Fernandes Call: +1 (650) 781 4080 Email: [emailprotected]marketresearch.com

See original here:
Stem Cell Therapy Market Size, Outlook on Key Growth Trends, Factors and Forecast to 2026 - ReportsPioneer

Wearable monitoring technology helps nurses avoid waking sleep-deprived patients – ABC News

By Stem Cell Treatment

Updated January 06, 2020 08:30:20

Since being diagnosed with Hodgkin's lymphoma 18 months ago, Aliona Grytsenko has spent much of her time in and out of hospital.

When the 22-year-old architecture student developed an infection after having a stem cell transplant, she had to be woken every hour to have her vital signs checked.

"It made it really hard to sleep and rest in the midst of having fevers and going through the treatment and side effects themselves. It's really difficult to manage that when you're so sleep-deprived," Ms Grytsenko said.

Registered nurse and researcher Elise Button has worked in cancer and palliative care for 10 years and said waking people up was one of the worst parts of the job.

"We routinely wake people up every four hours if they're more unwell we wake them up every hour or 15 minutes to do vital sign monitoring to make sure they're safe," Dr Button said.

"The sicker they are, the more we wake them up."

But new technology being trialled at the 20-bed Kilcoy Hospital, north-west of Brisbane, may put an end to what has been one of nurses' core responsibilities taking and recording vital signs.

Patients are being fitted with wearable body sensors that will automatically record their temperature, heart rate, oxygen levels and blood pressure.

Dr Button said it was a potential game-changer in nursing care.

"It gives us more time to focus on all the other roles that a nurse does that are important particularly communicating with people, sitting down and talking to them, while we know they're being safely monitored," Dr Button said.

"This allows people who are unwell to get sleep and rest, with peace of mind that they're being safely monitored."

The Metro North Hospital and Health Service's Adam Scott is overseeing the trial and says the feedback so far has been positive.

"Patients have commented they no longer have to be woken through the night. They can sleep through the process," Professor Scott said.

The wireless monitoring technology has been in development for a decade, but it is the first time in the world it has been put to the test by an entire hospital.

It could also help save hospital bottom lines.

"We have a growing level and burden of chronic disease, we have higher life expectancies and higher community expectations on how healthcare is provided," Professor Scott said.

"We know we have to move towards a value-based healthcare approach to better provide services and care for our patients."

The Australian distributor for the wireless monitoring device, Wearable Health Tech, estimates there are more than 100 million patient observations performed each year in Australia.

Company spokesman Ben Magid said the system not only gave time back to staff to spend on patient care, but improved patient safety through continuous monitoring.

"If patients do start to go downhill, staff are alerted so they can intervene sooner and prevent adverse events and complications from developing," Mr Magid said.

If the trial goes well, the technology could be used more widely, allowing patients to recover at home, while still being monitored by hospital staff.

Ms Grytsenko said it would have given her peace of mind.

"In the first few weeks after the stem cell transplant you don't know how you're going, you don't know, is that bad enough that I should call someone and ask or is it OK?'' Ms Grytsenko said.

Professor Scott said he believed it could also revolutionise rural medicine.

"We could have a command centre located in a metropolitan city where the specialist staff are sitting supervising and looking after and viewing patients that are located in a rural facility," Professor Scott said.

The trial will run until June.

Topics:healthcare-facilities,health-policy,health,government-and-politics,public-sector,medical-research,medical-procedures,doctors-and-medical-professionals,brisbane-4000,qld,maroochydore-4558,kilcoy-4515,australia

First posted January 06, 2020 06:56:17

Continued here:
Wearable monitoring technology helps nurses avoid waking sleep-deprived patients - ABC News

For Kaus, getting back on court is next step in recovery – Mankato Free Press

By Stem Cell Treatment

Justin Kaus has officiated thousands of basketball games in the last couple of decades, but on Friday night, in the locker room a few minutes before taking the court at Fitzgerald Gym, his resting heart rate was a rapid 118 beats per minute.

Its been a long time since Ive been that nervous and had that much adrenaline for a (junior-varsity) game, Kaus said, gathering with friends later Friday night to celebrate the way basketball officials often do on the weekend. It was awesome.

Kaus returned to the basketball court Friday for the first time since early February, having battled a form of leukemia that halted his professional and athletic career and nearly took his life.

It was great, he said, flexing some stiff muscles and joints. The interaction with coaches, talking with fans, interacting with the players ... you forget how much fun and rewarding that it.

It was more than 14 months since Kaus, 44, went to the clinic, feeling run down and with little energy or strength. He was diagnosed with a sinus infection, but two weeks passed, with stronger antibiotics, and he wasnt feeling any better.

He scheduled a visit to another doctor, who put him through a more extensive examination. He had blood drawn, and, as he was driving home, his doctor called and told him to get to the emergency room.

His hemoglobin level was dangerously low, and Kaus was taken by ambulance to the hospital in Rochester.

I went from thinking I had a sinus infection to having blood cancer in about 6 hours, Kaus said.

Thus began the yearlong process of trying to survive a diagnosis of primary myelofibrosis, a treatable form of leukemia. He continued his normal routine of work and officiating basketball games for a couple of months, trying not to get too worn down.

By February, after finding a couple of perfect donors for a bone-marrow transplant, the treatment became more rigorous and dangerous.

There was a round of chemotherapy in mid-February, followed by a stem cell transplant on Feb. 28. He was told to expect at least 100 days in the hospital, but that time more than doubled when he had to have his spleen removed in March. He developed an infection that required the removal of most of his colon, forcing a lifesaving surgery on May 25.

The doctor told me that if I didnt have my colon removed, it would likely burst, Kaus said. At that point, there would have been nothing more they could do for me.

There were a few weeks during the summer that he cant remember. At one point, he shut off his cell phone after staring at it one day, not sure what he was supposed to do with it. His friends stayed in touch through an online diary, written by his girlfriend, Delight Simpson.

In May, hundreds of Kaus friends gathered for a fundraiser, collecting thousands of dollars to help him with his monthly bills and extra expenses and exchanging hope for Kaus.

I cant thank people enough, he said, getting momentarily choked up with emotion. The support Ive received from my family, my work family, my basketball family has been unbelievable.

Kaus said that since that surgery, his recovery has been rapid and remarkable. Its about what he had originally been told had he not had any complications. Hes had more than 100 blood transfusions, and ironically, he now goes in a couple of times each month to have some blood removed.

After what Ive been through, its hard to watch them just throw that blood away, he said.

He weighed 153 pounds when the treatments began but slipped to 98 pounds. Hes worked hard to get his weight back to near normal, and hes done of lot of rehab work to regain strength. He was unable to lift 2 pounds at his most dire times. He still sees a doctor a couple of times each month, but those visits have become less frequent.

Until recently, he had to rely on Simpson, his daughter, Taylor, and his mom, Sally, to get around, but now hes driving again.

When he started rehab, he couldnt lift 10 pounds on the single-leg press, but hes now up to 125. Hes always been active, participating in sports, and his conditioning has slowly returned.

It felt so good to see him there, said Ben Kaus, Justins cousin and officiating partner on Friday. There was such a shock factor (a year ago) when we found out about his condition, and it took a while to sink in. For a while, we didnt know if Justin was going to be around much longer.

But at one of the visits, when it didnt look very good, he told us that he was going to make it. His positive attitude is what made the difference. Justin has always been like a big brother to me, and its great to have him back.

On Feb. 28, which will be one year from the stem-cell transplant, Kaus will have a checkup to see if the cancer is gone or he needs more treatment. Hell also know shortly after that if he needs to continue with colostomy and ileostomy bags or he can have surgery to reattach his colon to the digestive tract.

Until then, hes going to continue to increase his work hours and officiate basketball as much as his body can tolerate. He wanted to get that first assignment out of the way to see how he felt, then he can plan the next couple of months. Being on the court is as much of a mental triumph as a physical milestone.

In August, I had pretty much written off this season, he said. In early December, it was my 40th physical therapy session in Mankato, my physical therapist suggested that I talk with some coach and go to a scrimmage to simulate basketball movements.

Its the coolest thing to be back on the court, he said. Ive gotten so many messages and words of encouragement and support from the start to this point. This was another step in getting back to normal, and its something Ive worked hard for.

Its never been about me, but the camaraderie being around other officials and telling stories and talking about the games has been very therapeutic. We dont have to (officiate basketball games). We do it because we still enjoy the games and we want to give something back. I hope the coaches, the players, the fans appreciate what we do, but in the end, all that matters is were spending time in the gym, around a game that we love.

Follow Chad Courrier on Twitter @ChadCourrier.

Continued here:
For Kaus, getting back on court is next step in recovery - Mankato Free Press

Animal Stem Cell Therapy Market: Growth Trends, Sales Outlook, Revenue, Market Toppers, End-Users, Major Regions – ReportsPioneer

By Stem Cell Treatment

Animal Stem Cell Therapy market research report provides the details about Industry Chain structure, Market Competition, Market Size & Share, SWOT Analysis, Technology, Cost, Raw Materials, Consumer Preference, Development & Trends, Regional Forecast, Company & Profile and Product & Service.

Animal Stem Cell Therapy market research report also gives information on the Trade Overview, Policy, Regional Market, Production Development, Sales, Regional Trade, Business Operation Data, Market Features, Investment Opportunity, Investment Calculation and other important aspect of the industry.

Request a Sample of Animal Stem Cell Therapy Market Research Report with 117 pages and Analysis of Top Key Players at https://www.insidemarketreports.com/sample-request/4/133116/Animal-Stem-Cell-Therapy

The main objectives of the research report elaborate the overall market overview on Animal Stem Cell Therapy market dynamics, historic volume and value, robust market methodology, current & future trends, Porters Five Forces Analysis, upstream and downstream industry chain, new technological development, cost structure, government policies & regulations, etc. Major companies, company overview, financial data, products and services, strategy analysis, key developments market competition, industry competition structure analysis, SWOT Analysis, etc.

Further Animal Stem Cell Therapy market research report provides regional marketanalysis with production, sales, trade & regional forecast. it also provides market investment plan like product features, price trend analysis, channel features, purchasing features, regional & industry investment opportunity, cost & revenue calculation, economic performance evaluation etc.

The Animal Stem Cell Therapy industry development trends and marketing channels are analyzed. Finally, the feasibility of new investment projects is assessed, and overall research conclusions offered.

Report Scope

The tunnel ventilation market has been segmented based on different types and application. In order to provide a holistic view on the market current and future market demand has been included in the report.

Major players covered in this report are MediVet Biologic, VETSTEM BIOPHARMA, J-ARM, Celavet, Magellan Stem Cells, U.S. Stem Cell, Cells Power Japan, ANIMAL CELL THERAPIES, Animal Care Stem, Cell Therapy Sciences, VetCell Therapeutics, Animacel, Aratana Therapeutics etc.

Major Points covered in this report are as below

Owning our reports and subscribing our eco-system will help you solve the following issues:

Our research and insights help our clients to foresee upcoming revenue pockets and growth areas. This help our client to invest or divest their resources.

It is extremely crucial to have a fair understanding of market sentiments for a strategy. Our insights help to have a hawk-eye view on a market sentiment. We keep this surveillance by engaging with Key Opinion Leaders of a value chain of each industry we track.

Our research ranks investments centers of market by considering their future demands, returns and profit margins. Our clients can focus on most prominent investment centers by procuring our market research.

Our research and insights help our clients in identifying compatible business partners.

Buy this report online athttps://www.insidemarketreports.com/buy-now/4/133116/Animal-Stem-Cell-Therapy/single

Why Inside Market Reports:

For all your Research needs, reach out to us at:

Email: [emailprotected]

Phone: +1-617-230-0741

Here is the original post:
Animal Stem Cell Therapy Market: Growth Trends, Sales Outlook, Revenue, Market Toppers, End-Users, Major Regions - ReportsPioneer

→←